Elsevier

Medical Hypotheses

Volume 36, Issue 3, November 1991, Pages 185-189
Medical Hypotheses

Innovation vs. quality control: An ‘unpublishable’ clinical trial of supplemental ascorbate in incurable cancer

https://doi.org/10.1016/0306-9877(91)90127-KGet rights and content

Abstract

A computerized data bank was created recording the details of all cancer patients attending three district general hospitals in West Central Scotland over a 4.5 year period 1978–1982. At the conclusion of the trial, the records of 2804 individual patients were available for study, of whom 1826 had reached an incurable stage. 294 of these incurable cancer patients had received supplemental ascorbate at some stage in their illness, whereas 1532 had not, and served as controls. Analysis showed that the ascorbate-supplemented patients had a median overal survival time (343 days) almost double that of the controls (180 days). Our difficulties in having this simple, but important, observation published are briefly recounted in the introduction.

References (11)

  • E Cameron

    Protocol for the use of vitamin C in the treatment of cancer

    Medical Hypotheses

    (1991)
  • ET Creagan et al.

    Failure of high-dose vitamin C (ascorbic acid) to benefit patients with advanced cancer: a controlled trial

    N Eng J Med

    (1979)
  • CG Moertel et al.

    High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy

    N Eng J Med

    (1985)
  • DF Horrobin

    The philosophical basis of peer review and the suppression of innovation

    JAMA

    (1990)
  • E Richards
There are more references available in the full text version of this article.

Cited by (0)

View full text